March 16th 2024
A phase 2 trial showed favorable antitumor activity when tislelizumab plus chemotherapy was used for patients with locally advaned cervical cancer.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
HPV Vaccine Not Linked to Serious Complications in Adult Women
October 22nd 2017A large cohort study found no concerning safety issues associated with the use of human papillomavirus (HPV) vaccine in adult women. There was an increased rate of celiac disease, but this may be related to general underdiagnosis of the condition and its unmasking at vaccination visits.
USPSTF Proposes New Guidelines for Cervical Cancer Screening
October 11th 2017The USPSTF issued a new draft recommendation for cervical cancer screening, recommending screening with cervical cytology every 3 years for women aged 21 to 29, and offering a choice between cytology every 3 years and high-risk human papillomavirus testing every 5 years for those aged 30 to 65 years.
Some Older Women Still Need Cervical Cancer Screening
May 17th 2017The number of women who undergo regular screening for cervical cancer drops as they get older, and while this is acceptable if women have been followed regularly until the age of 65 years, women who are not up to date with screening should be screened when they are older.
Sexual and urinary morbidities resulting from treatment of pelvic malignancies are common. Awareness of these complications is critical in order to properly counsel patients regarding potential side effects and to facilitate prompt diagnosis and management.
HIV Infection Decreases Survival in Women With Invasive Cervical Cancer
August 30th 2016HIV infection significantly decreases survival among women with invasive cervical cancer, according to a study conducted in Botswana. This was the case even though most women with HIV received antiretroviral therapy.
Cisplatin/Paclitaxel Plus RT Offers Good Results in Advanced Cervical Cancer
June 22nd 2016A concurrent chemotherapy and radiotherapy regimen with cisplatin and paclitaxel yielded a good response rate and strong long-term survival outcomes in patients with locally advanced or recurrent cervical cancer.
AXAL Immunotherapy Well-Tolerated in Recurrent Metastatic Cervical Cancer
June 16th 2016A live attenuated bioengineered bacteria-vectored vaccine immunotherapy is well tolerated and appears to be associated with promising overall survival among women with persistent/recurrent metastatic cervical cancer.
ASCO Releases Resource-Stratified Invasive Cervical Cancer Guidelines
May 25th 2016ASCO has released a clinical practice guideline on invasive cervical cancer. For the first time, ASCO created the guideline based on resource availability, tailoring recommendations to support basic- or limited-resource settings.
Uptick in HPV Vaccinations Highest in Hispanic, High Poverty Communities
January 15th 2016Adolescent girls who live in predominantly Hispanic and high poverty communities are more likely to have had at least one HPV vaccine dose compared to girls in low poverty communities and those with different ethnic make up.